Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National PKU Alliance | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
While previous PKU intervention research has largely focused on pharmacological treatment of elevated Phe levels, the adaptation of evidence-based psychosocial therapy holds promise for addressing cognitive and psychological symptoms and significantly improving quality of life. Study goals include: (1) to demonstrate the efficacy and feasibility of a short-term skills-based intervention (Show Me FIRST) for anxiety and depression in adolescents with PKU, and (2) to further establish the psychometric validity of novel assessment measures recently developed by the Investigators that utilize ecological momentary assessment (EMA) to capture "in the moment" neurocognitive and psychological function. The Investigators propose to conduct a randomized controlled trial wherein 30 adolescents with PKU will be randomized to either an immediate intervention group or wait-list/delayed intervention group.
A sample of 30 adolescents (age 10-17) with PKU and a history of elevated anxiety and/or depression symptomatology will be recruited to participate in a randomized control trial. Following screening and informed consent, participants will be randomized to an immediate intervention group (n=15) or wait-list/delayed intervention group (n=15). Participants will receive the 10-week Show Me First program for treatment of anxiety and depression. Participants will complete extensive psychological and neurocognitive evaluations at three timepoints: Weeks 0, 11, and 22. The assessments and intervention will all be administered remotely via secure videoconference and cell-phone based applications.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Immediate Intervention Group | Other |
| |
| Wait List / Delayed Intervention Group | Other |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Show Me FIRST coping skills intervention | Behavioral | Show Me FIRST is a flexible, transdiagnostic intervention organized around well-tested principles of youth psychotherapeutic change. |
| Measure | Description | Time Frame |
|---|---|---|
| PROMIS Anxiety & Depression scales | Patient-reported outcome (PRO) measure of anxiety & depression symptoms | Weeks 0, 11, & 22 |
| Test My Brain phone-based EMA cognitive test | Performance-based measure of cognitive skill & attention | Weeks 0, 11, & 22 |
| Measure | Description | Time Frame |
|---|---|---|
| Behavior Rating Inventory of Executive Function (BRIEF) | Patient-reported outcome (PRO) measure of everyday symptoms of executive problems | Weeks 0, 11, & 22 |
| Blood Phenylalanine Levels | Weeks 0, 5, 11, 16, & 22 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Shawn Christ | Contact | 573-884-8140 | christse@missouri.edu |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Missouri | Recruiting | Columbia | Missouri | 65201 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010661 | Phenylketonurias |
| ID | Term |
|---|---|
| D020739 | Brain Diseases, Metabolic, Inborn |
| D001928 | Brain Diseases, Metabolic |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
Wait-list Control Design
Not provided
Not provided
Not provided
Not provided
| ADHD Rating Scale - 4th version (ADHD-RS-IV) | Patient-reported outcome (PRO) measure of ADHD symptoms | Weeks 0, 11, & 22 |
| Executive Function, Attention, and Speed Symptom Inventory (EASSI) for PKU | Patient-reported outcome (PRO) measure of cognitive symptoms | Weeks 0, 11, & 22 |
| Rey Auditory Verbal Learning Test (Rey AVLT) | Performance-based measure of memory & learning | Weeks 0, 11, & 22 |
| Stop Signal Task (SST) | Performance-based measure of inhibitory ability | Weeks 0, 11, & 22 |
| Revised Children's Anxiety and Depression Scale (RCADS) | Patient-reported outcome (PRO) measure of anxiety & depression symptoms | Weeks 0, 11, & 22 |
| Behavior & Feelings Survey (BFS) | Patient-reported outcome (PRO) measure of internalizing & externalizing problems | Weeks 0, 11, & 22 |
| Adolescent Insomnia Questionnaire (AIQ) | Patient-reported outcome (PRO) measure of sleep problems | Weeks 0, 11, & 22 |
| Global Impression Scale | Patient-reported outcome (PRO) measure of overall symptom severity and improvement | Weeks 0, 11, & 22 |
| D009422 | Nervous System Diseases |
| D000592 | Amino Acid Metabolism, Inborn Errors |
| D008661 | Metabolism, Inborn Errors |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |